Received Jan 20, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
wife had a headache; wife had few body aches; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of headache in a female patient who received Herpes zoster (Shingrix) for prophylaxis. Concomitant products included VARICELLA ZOSTER VACCINE RGE (CHO) (SHINGRIX). On 14-JAN-2026, the patient received the 2nd dose of Shingrix. In JAN-2026, an unknown time after receiving Shingrix, the patient experienced headache (Verbatim: wife had a headache) and general body pain (Verbatim: wife had few body aches). The outcome of the headache and general body pain were not reported. It was unknown if the reporter considered the headache and general body pain to be related to Shingrix. It was unknown if the company considered the headache and general body pain to be related to Shingrix. Additional Information: GSK Receipt Date: 15-JAN-2026 The reporter reported that everyone was different in their reactions to the shot. The patient (wife) had second dose yesterday 2 months after the first shot. The patient had a headache and a few body aches, but nothing worse than that which was pretty similar to covid vaccine reactions. The batch number was not provided, and we are unable to contact the reporter. This case US2026AMR008450 was reported by same reporter.; Sender's Comments: US-GSK-US2026AMR008450:same reporter different patient.
SHINGRIX